Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-16-013561
Filing Date
2016-03-29
Accepted
2016-03-29 17:27:42
Documents
3
Effectiveness Date
2016-03-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2016additionaldefinitivep.htm DEFA14A 42914
2 cumberlandlogo.jpg GRAPHIC 12534
3 internetimage.jpg GRAPHIC 8352
  Complete submission text file 0001628280-16-013561.txt   67502
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEFA14A | Act: 34 | File No.: 001-33637 | Film No.: 161536436
SIC: 2834 Pharmaceutical Preparations